Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

…, J Li, P Niu, B Yang, H Wu, W Wang, H Song, B Huang… - The lancet, 2020 - thelancet.com
Background In late December, 2019, patients presenting with viral pneumonia due to an
unidentified microbial agent were reported in Wuhan, China. A novel coronavirus was …

A novel coronavirus from patients with pneumonia in China, 2019

…, X Li, B Yang, J Song, X Zhao, B Huang… - New England journal …, 2020 - Mass Medical Soc
In December 2019, a cluster of patients with pneumonia of unknown cause was linked to a
seafood wholesale market in Wuhan, China. A previously unknown betacoronavirus was …

In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS …

X Yao, F Ye, M Zhang, C Cui, B Huang… - Clinical infectious …, 2020 - academic.oup.com
Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first broke
out in 2019 and subsequently spread worldwide. Chloroquine has been sporadically used …

Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China

A Wu, Y Peng, B Huang, X Ding, X Wang, P Niu… - Cell host & …, 2020 - cell.com
An in-depth annotation of the newly discovered coronavirus (2019-nCoV) genome has
revealed differences between 2019-nCoV and severe acute respiratory syndrome (SARS) or …

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

…, M Xu, Z Lou, W Huang, W Xu, B Huang… - The Lancet infectious …, 2021 - thelancet.com
Background The ongoing COVID-19 pandemic warrants accelerated efforts to test vaccine
candidates. We aimed to assess the safety and immunogenicity of an inactivated severe …

Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS–coronavirus 2

J Shi, Z Wen, G Zhong, H Yang, C Wang, B Huang… - Science, 2020 - science.org
Severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2) causes the infectious
disease COVID-19 (coronavirus disease 2019), which was first reported in Wuhan, China, in …

[HTML][HTML] The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice

L Bao, W Deng, B Huang, H Gao, J Liu, L Ren, Q Wei… - Nature, 2020 - nature.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of coronavirus
disease 2019 (COVID-19), which has become a public health emergency of international …

Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2

H Wang, Y Zhang, B Huang, W Deng, Y Quan, W Wang… - Cell, 2020 - cell.com
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) threatens global public health. The development of a …

[HTML][HTML] Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease

…, F Yu, Q Wang, Y Wu, C Zhao, H Sun, B Huang… - Nature …, 2020 - nature.com
COVID-19 was declared a pandemic on March 11 by WHO, due to its great threat to global
public health. The coronavirus main protease (M pro, also called 3CLpro) is essential for …

Morphogenesis and cytopathic effect of SARS-CoV-2 infection in human airway epithelial cells

…, Z Liu, C Liang, W Wang, F Ye, B Huang… - Nature …, 2020 - nature.com
SARS-CoV-2, a β-coronavirus, has rapidly spread across the world, highlighting its high
transmissibility, but the underlying morphogenesis and pathogenesis remain poorly understood. …